CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 399 enrolled
Drug / intervention
CP-690,550 +5 moredrug
Likely dose
CP-690,550 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00960440
NCT00960440Phase 3Completed
CompareCT.gov

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors

Pfizer·interventional·Posted Aug 17, 2009·Updated Dec 19, 2018

In Brief

A Phase 3 clinical trial evaluating CP-690,550 and Placebo for Arthritis, Rheumatoid. Completed, enrolled 399 participants across 92 sites in 14 countries.

Detailed Summary

This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesAustralia, Austria, Belgium, Brazil, Canada, France, Germany, Ireland, Italy, Puerto Rico, South Korea, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2009
Enrollment StartOct 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.9 years ago

Interventions

CP-690,550drug

Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.

CP-690,550drug

Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.

Placebodrug

Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.

CP-690,550drug

Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.

Placebodrug

Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.

CP-690,550drug

Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.